What question did this study set out to answer?

To evaluate and compare the efficacy and safety of dual antihypertensive regimens against a triple combination therapy in patients diagnosed with stage 2 hypertension.

January 1, 2014JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCHOpen Access

Comparative Efficacy and Safety of Triple Therapy (Ramipril, Telmisartan, Hydrochlorothiazide) Vs Dual Anti Hypertensive Therapy (Ramipril or Telmisartan, Hydrochlorothiazide) in Stage 2 Hypertensive Patients

View Full Paper

Ask AI

Bookmark

Why the study?

Does triple therapy (ramipril, telmisartan, hydrochlorothiazide) improve blood pressure reduction compared to dual therapy in patients with stage 2 hypertension?

Population

88 patients with stage 2 hypertension without co-morbid conditions

Comparison

Ramipril 2.5 mg plus telmisartan 20 mg plus… vs Ramipril 5 mg plus hydrochlorothiazide 12.5 mg…

Design

RCT, randomized, open label

Follow-up

up to 24 weeks

Authors

BBBharat BhushanNorthwestern University

Discussion

Member takes

Implication

Triple therapy adds no BP reduction benefit over dual therapy in stage 2 hypertension; supports dual regimens to limit adverse events.

Key Points

To evaluate and compare the efficacy and safety of dual antihypertensive regimens against a triple combination therapy in patients diagnosed with stage 2 hypertension.
Conducted a prospective, open-label, randomized comparative trial in 88 patients with stage 2 hypertension without co-morbidities across 24 weeks.
Assigned patients to ramipril (5 mg) plus hydrochlorothiazide (12.5 mg), telmisartan (40 mg) plus hydrochlorothiazide (12.5 mg), or ramipril (2.5 mg) plus telmisartan (20 mg) plus hydrochlorothiazide (12.5 mg).
Evaluated left ventricular function using echocardiography and recorded all adverse drug reactions during follow-up.
All three groups achieved statistically significant reductions in systolic and diastolic blood pressure from baseline (p<0.0001), with no statistically significant differences observed between the groups.
A total of 15 adverse drug reactions occurred, with the triple therapy arm exhibiting the highest percentage and dry cough (8 cases) being the most prevalent event.
Left ventricular function parameters on echocardiography did not show significant changes from baseline in any of the three treatment arms.

Structured PICO

Does triple therapy (ramipril, telmisartan, hydrochlorothiazide) improve blood pressure reduction compared to dual therapy in patients with stage 2 hypertension?

Population

88 patients with stage 2 hypertension without co-morbid conditions

Intervention

Ramipril 2.5 mg plus telmisartan 20 mg plus hydrochlorothiazide 12.5 mg (triple therapy)

Comparator

Ramipril 5 mg plus hydrochlorothiazide 12.5 mg OR telmisartan 40 mg plus hydrochlorothiazide 12.5 mg (dual therapy)

Outcome

Fall in systolic and diastolic blood pressuresurrogate

Triple therapy with low-dose ramipril, telmisartan, and hydrochlorothiazide is equally effective but not superior to dual therapy in reducing blood pressure in stage 2 hypertension, while carrying a higher risk of adverse events.

Cite This Study

Bharat Bhushan (2014) studied this question.

synapsesocial.com/papers/6a7c193701db1a7270ed47c8 https://doi.org/10.7860/jcdr/2014/8851.4720

View Full Paper

Ask AI

Bookmark

Comparative Efficacy and Safety of Triple Therapy (Ramipril, Telmisartan, Hydrochlorothiazide) Vs Dual Anti Hypertensive Therapy (Ramipril or Telmisartan, Hydrochlorothiazide) in Stage 2 Hypertensive Patients

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Comparative Efficacy and Safety of Triple Therapy (Ramipril, Telmisartan, Hydrochlorothiazide) Vs Dual Anti Hypertensive Therapy (Ramipril or Telmisartan, Hydrochlorothiazide) in Stage 2 Hypertensive Patients

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider